BI 2536 was the first selective PLK1 inhibitor investigated in clinical trials with patients who have various advanced and/or metastatic solid tumors including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, and ovarian cancer [61]. This evidence concerns the gene PLK1 and hepatocellular carcinoma.